A Phase I Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidate AdCh63 ME-TRAP, Alone and With MVA ME-TRAP, Using a Prime-Boost Delivery Schedule.

Trial Profile

A Phase I Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidate AdCh63 ME-TRAP, Alone and With MVA ME-TRAP, Using a Prime-Boost Delivery Schedule.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2012

At a glance

  • Drugs ME-TRAP malaria DNA vaccine Okairos (Primary)
  • Indications Falciparum malaria
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Mar 2011 Planned End Date changed from 1 Mar 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 21 Jan 2010 Planned number of patients changed from 44 to 54 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top